Utilizing one broad exome panel has raised many issues of poor coverage

Most whole exome sequencing panels often cover less of the whole exome than required, with data indicating
that 50 percent of exons have lower than 30x average coverage. Due to the low-coverage regions,
WES can miss critically important variant regions.

Variant calling and clinical interpretation still requires extensive expertise and time

Clinical exome sequencing data analysis still demands both technical expertise and significant time expenditure.
Clinical interpretation of various detected variants is very challenging as it involves a comprehensive
understanding of variants, drugs, guidelines, etc.

Diagnose Rare Disease with CES/DES Panel

The G-Mendeliome Clinical Exome Sequencing Panel, CES (also known as the Diagnostics Exome Sequencing panel, DES, at GC Genome) was developed from the needs of GC Genome (https://www.gc-genome.com), the largest clinical NGS service provider in Korea.

CES solved the problem of poor diagnostics resulting from the large number of genes omitted from the inherited disease
panels of Companies A and B (Figure 1) and reduced costs by removing areas from both panels irrelevant to diagnosis.

GC Genome previously used the panels of both Company A and B, but have since replaced their workflow
using the G-Mendeliome CES Panel.

Comparison data : ZNF419 gene

Figure 1. Clinically significant regions of interest absent from competitor’s products

Figure 2. Customer Testimonial of GC Genome

Celemics Analysis Service (CAS) Workflow

Celemics' CES Panel is bundled with a free-of-charge CAS Secondary Report and powerful,
cost-effective Clinical Report, both optimized for your real-life clinical requirements.